Market Report for Week Ending 13/09/2013

NW Brown Group

In this week’s market report Oliver Phillips talks about GlaxoSmithKline…

Market Commentary

The FTSE 100 index rose 0.6% to 6583.8 as investor confidence in the UK’s economic recovery was boosted by data revealing a higher-than-expected drop in jobless claims and a fall in the nation’s unemployment rate.

 Stocks in focus: GlaxoSmithKline

What does it do?
GlaxoSmithKline is a global healthcare company that researches and develops a broad range of innovative medicines, vaccines and consumer health brands.

How is it doing?
Following on from the recent investigation into alleged mis-selling practices in China, the group’s risk profile has been increased by news last week that the US Food and Drug Administration (FDA) has issued guidance for generic competition to its $8-billion-a-year asthma treatment Advair, for which GSK’s main US patent expired in 2010. Unique among blockbusters, the drug has thus far remained free of generic competition thanks to the difficulty of…

View original post 216 more words

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s